<DOC>
	<DOCNO>NCT01376284</DOCNO>
	<brief_summary>The study design investigate safety efficacy dutasteride capsule 0.5 mg collect required number Japanese subject benign prostatic hyperplasia ( BPH ) order identify concern problem , , efficacy safety use post-marketing clinical setting .</brief_summary>
	<brief_title>Drug Use Investigation AVOLVE ( BPH )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Must male subject Use dutasteride capsule first time Subjects hypersensitivity dutasteride 5Î± reductase inhibitor Subjects severe hepatic function disorder Dutasteride capsule shall use female child</criteria>
	<gender>Male</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>